ReviewClinical & developmental immunology2012
Cytotoxic chemotherapy and CD4+ effector T cells: an emerging alliance for durable antitumor effects.
Review in Clinical & developmental immunology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 57 citations in OpenAlex.
- Phase II Study of the PD-1 Inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory Mature T-cell Lymphoma.Clinical lymphoma, myeloma & leukemia · 2019Trial
- Efficacy and safety of secondary induction radiotherapy in locally advanced resectable esophageal squamous cell carcinoma with poor responses to neoadjuvant immunochemotherapy: a retrospective study.Frontiers in immunology · 2026Article
- Beyond Structure: The Dynamic Role of the Extracellular Matrix Components in Immune Evasion.Cancer communications (London, England) · 2026Review
- KIF20A as a driver of anti-PD-1 resistance via PD-L1 downregulation in NSCLC: a biomarker validation and tumor microenvironment analysis.BMC cancer · 2025Article
- A Simultaneous Presentation of Nasopharyngeal Carcinoma and Latent Cervical Tuberculosis: Insights into a Complex Case.Diagnostics (Basel, Switzerland) · 2025Article
- Single-cell transcriptomic profiling reveals immune cell heterogeneity in acute myeloid leukaemia peripheral blood mononuclear cells after chemotherapy.Cellular oncology (Dordrecht, Netherlands) · 2024Article
- Article
- Acute inflammatory reaction during anti-angiogenesis therapy combined with immunotherapy as a possible indicator of the therapeutic effect: Three case reports and literature review.Frontiers in oncology · 2023Review
- Immunotherapy for advanced hepatocellular carcinoma: From clinical trials to real-world data and future advances.World journal of clinical oncology · 2022Review
- Article
- Associations among cytokines, EGF and lymphocyte subpopulations in patients diagnosed with advanced lung cancer.Cancer immunology, immunotherapy : CII · 2021Article
- Identification of an immunogenic DKK1 long peptide for immunotherapy of human multiple myeloma.Haematologica · 2021Article
- Spatial Distribution and Prognostic Implications of Tumor-Infiltrating FoxP3- CD4+ T Cells in Biliary Tract Cancer.Cancer research and treatment · 2021Article
- Persistent STAT5 activation reprograms the epigenetic landscape in CD4Science immunology · 2020Article
- Circulating activated lymphocyte subsets as potential blood biomarkers of cancer progression.Cancer medicine · 2020Article
- FoxP3 promotes lymph node metastasis in patients with papillary thyroid carcinoma complicated with Hashimoto's thyroiditis.Translational cancer research · 2020Article
- Chimeric antigen receptor-modified T cell therapy in chronic lymphocytic leukemia.Journal of hematology & oncology · 2018Review
- Overexpression of kinesin family member 20A is associated with unfavorable clinical outcome and tumor progression in epithelial ovarian cancer.Cancer management and research · 2018Article
- Article
- The distribution and function of human memory T cell subsets in lung cancer.Immunologic research · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Standard cytotoxic chemotherapy can initially achieve high response rates, but relapses often occur in patients and represent a severe clinical problem. As increasing numbers of chemotherapeutic agents are found to have immunostimulatory effects, there is a growing interest to combine chemotherapy and immunotherapy for synergistic antitumor effects and improved clinical benefits. Findings from recent studies suggest that highly activated, polyfunctional CD4+ effector T cells have tremendous potential in strengthening and sustaining the overall host antitumor immunity in the postchemotherapy window. This review focuses on the latest progresses regarding the impact of chemotherapy on CD4+ T-cell phenotype and function and discusses the prospect of exploiting CD4+ T cells to control tumor progression and prevent relapse after chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.